Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Alfasigma S.p.a.

Tecnogen S.c.p.a.

Menarini Ricerche S.p.a.

Sigma-tau Industrie Farmaceutiche

Metheresis Translational Research Sa

Rita De Santis

Paolo Carminati

Paolo Maria Comoglio

Carlo A Nuzzolo

Giovanni Salvatori

Antonio Inforzato

Anna Maria Anastasi

Antonio Mele

Saverio Alberti

Giovanna Palombo

Ragnar Lindstedt

Giovanna Borsellino

Fiorella Petronzelli

Luca Battistini

Annamaria Coscarella

Angela Pelliccia

Cristina Carloni

Carla Boccaccio

Carlo Antonio Nuzzolo

Anna Anastasi

The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.

Pharmaceutical composition of oxidised avidin suitable for inhalation

The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NHresidues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART&#xae;) or degenerative or genetic diseases.

Oxidized avidin with high residency time in the treated tissues

An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumor selectivity.

Anti-EpCAM antibody and uses thereof

An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A-D region of human tenascin.

Anti-human tenascin monoclonal antibody

The present invention discloses a method of generation of antigen presenting cells, comprising: a collecting said cells from a subject, b. activating said collected cells; c. culturing and optionally expanding ex vivo said activated cells; d. treating said cultured and optionally expanded cells with DNA hypomethylating agents so that said cells concomitantly express multiple tumor associated antigens. The cells obtainable according to the method of the present invention, as well as the cellular components thereof whether alone or in combination with said cells, are useful for prevention and treatment of malignancies of different histotype that constitutively express one or more of the multiple tumor associated antigens that are expressed in said cells. Conveniently, said cells and/or cellular components are in the form of a vaccine. Said vaccines are advantageous over the prior art in that as they concomitantly express multiple/all methylation-regulated tumor associated antigens.

Antigen presenting cells, method for their preparation and their use for cancer vaccines

Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.

Deglycosylated and desialidated long pentraxin PTX3

A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.

Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (&#x2014;NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitropretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.

Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy

The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and reumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole. The present invention further discloses a method for inhibiting &ggr;&dgr; T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.

Growing community of inventors

Pomezia, Italy

Rita De Santis